The Austrian Breast and Colorectal Cancer Study Group trial 12 (ABCSG-12) compared an LH-RH analogue plus TAM with an LH-RH analogue plus an aromatase inhibitor as an adjuvant therapy in premenopausal women with endocrine-responsive breast cancer (20). The gene discussed is CYP19A1; the disease is breast cancer.